Antimicrobial Dressings for Burn Wound Infection Control

描述(由申请人提供)：在美国，每年有100,000-300,000人因烧伤而住院，估计有200万人受到烧伤。在这两百万人中，最终将有超过12000人死于烧伤相关感染。事实上，感染是烧伤患者死亡的最大原因。烧伤创面感染可以追溯到几个来源，包括：患者自己的皮肤和胃肠道、烧伤护理机构、其他患者以及患者的护理人员。该SBIR第一阶段项目涉及一种抗菌织物的制备，该织物将用作烧伤创面敷料，以控制感染。抗菌基团将共价连接到织物材料上。这项技术将取代目前使用的局部抗菌剂。目前的外用药物已被证明具有不良的副作用，由于耐药微生物的出现，它们对感染控制的有效性继续下降。这一第一阶段项目的目标是准备一种抗菌织物，这种织物对广泛的烧伤创面病原体有效，对人体皮肤细胞没有细胞毒性，因此不会抑制愈合过程。

DESCRIPTION (provided by applicant): 100,000 - 300,000 hospitalizations occur annually in the United States as a result of an estimated two million people who suffer burn injuries. More than 12,000 of these two million will eventually die of burn-related infections. In fact, infections are the largest cause of death in burn patients. Burn wound infections can be traced to several sources including: the patient's own skin and gastrointestinal tract, the burn care facility, other patients, and from the patient's caregivers. This SBIR Phase I project concerns the preparation of an antimicrobial fabric to be used as a burn wound dressing for infection control. An antimicrobial group will be covalently linked to the fabric material. This technology will replace the currently employed topical antimicrobial agents. Current topical agents have been shown to have undesirable side effects and their effectiveness for infection control continues to decline due to the emergence of resistant microorganisms. The goal of this Phase I project is to prepare an antimicrobial fabric that is effective against a broad spectrum of the common burn wound pathogens and is not cytotoxic to human skin cells and therefore will not inhibit the healing process.